Sugammadex: the first selective binding reversal agent for neuromuscular block☆☆☆
Abstract
Sugammadex is a novel cyclodextrin, the first in a new class of selective binding reversal agents that terminates neuromuscular block (NMB) with the steroidal nondepolarizing agents, rocuronium and vecuronium. Sugammadex can reverse a moderate or deep NMB. The dose required depends on the level of NMB that needs to be reversed. Smaller doses are sufficient for a moderate versus deep NMB. In October 2007, a new drug application for sugammadex was submitted to the U.S. Food and Drug Administration (FDA). The FDA issued a not-approvable letter in July 2008. The manufacturer continues clinical trials.
Keywords: Cyclodextrin, Encapsulation, Muscle relaxant reversal, Neuromuscular block, Selective binding reversal agent, Sugammadex
To access this article, please choose from the options below
☆ There were no sources of funding for the preparation of this manuscript.
☆☆ Dr. Kovac has received grant support from Organon (now Schering-Plough) and participated on the Speakers Bureau for Organon.
PII: S0952-8180(09)00218-9
doi:10.1016/j.jclinane.2009.05.002
© 2009 Elsevier Inc. All rights reserved.
